论文部分内容阅读
目的 系统评价贝伐单抗联合STUPP方案治疗新诊断胶质瘤患者的有效性与安全性.方法 计算机检索PubMed、EMbase、The Cochrane Library、CBM、CNKI、VIP和Wan Fang Data数据库, 搜集贝伐单抗联合STUPP方案治疗新诊断恶性胶质瘤患者的随机对照试验 (RCTs), 检索时限均从建库至2017年9月.由2位评价员独立筛选文献、提取资料并评价纳入研究的偏倚风险后, 采用RevMan 5.3软件进行Meta分析.结果 共纳入6个RCTs, 合计2 835例患者.Meta分析结果显示:与对照组相比, 贝伐单抗联合STUPP方案组PFS明显延长[HR=0.69, 95％CI (0.62, 0.77), P＜0.000 01].但贝伐单抗联合STUPP方案组的三级及三级以上不良反应发生率明显高于对照组, 差异有统计学意义 (P＜0.05).结论 当前证据表明, 贝伐单抗联合STUPP方案在治疗新诊断胶质瘤患者相比单用STUPP方案可延长PFS, 但易出现更多的不良反应.受纳入研究质量和数量限制, 上述结论有待更多高质量的RCTs进一步验证.“,”Objectives To systematically review the efficacy and safety of bevacizumab combined with STUPP regimen for newly diagnosed glioblastoma. Methods PubMed, EMbase, the Cochrane Library, CBM, CNKI, VIP and Wan Fang Data databases were searched to obtain randomized controlled trials (RCTs) of bevacizumab combined with STUPP regimen for newly diagnosed glioblastoma patients from inception to September 2017. Two reviewers independently screened literature, extracted data and assessed the risk of bias of included studies. Meta-analysis was then performed using RevMan 5.3 software. Results A total of 6 RCTs involving 2 835 patients were included. The results of meta-analysis showed that: the bevacizumab combined with STUPP regimen group was superior to the control group on PFS (HR=0.69, 95％CI 0.62 to 0.77, P＜0.000 01). But the adverse events rate at the three and above three levels was significantly higher than the control group (P＜0.05). Conclusions Current evidence shows that bevacizumab combined with STUPP regimen for newly diagnosed glioblastoma can significantly prolong the PFS. The treatment group performs not as well as the control group on adverse event rate. Due to the limited quality and quantity of the included studies, more high-quality studies are required to verify above conclusions.